Company Description
Ainos, Inc., a dual-platform company, focusing artificial intelligence–based smelltech technologies and immune therapeutics.
It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data.
The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women’s health sectors.
In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases.
The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
| Country | United States |
| Founded | 1984 |
| Industry | Scientific & Technical Instruments |
| Sector | Technology |
| Employees | 41 |
| CEO | Chun-Hsien Tsai |
Contact Details
Address: 3050 Post Oak Boulevard, Suite 510-T80 Houston, Texas 77056 United States | |
| Phone | 281 898 6586 |
| Website | ainos.com |
Stock Details
| Ticker Symbol | AIMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1014763 |
| CUSIP Number | 00902F402 |
| ISIN Number | US00902F4028 |
| Employer ID | 75-1974352 |
| SIC Code | 3577 |
Key Executives
| Name | Position |
|---|---|
| Chun-Hsien Tsai | Chief Executive Officer, President and Chairman of the Board |
| Hsin-Liang Lee | Chief Financial Officer |
| Chih-Heng Lu | Director of Corporate Developoment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 17, 2026 | SCHEDULE 13D/A | Filing |
| Apr 17, 2026 | SCHEDULE 13D/A | Filing |
| Apr 17, 2026 | SCHEDULE 13D/A | Filing |
| Apr 15, 2026 | SCHEDULE 13D/A | Filing |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 30, 2026 | 8-K | Current Report |
| Feb 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 30, 2026 | SCHEDULE 13D/A | Filing |